Genzyme in India

Life is a health journey, with ups and downs, which can be big or small, lifelong or momentary.


We, at Sanofi, are there for those challenges, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.


Sanofi, Empowering Life.

April 28, 2017: Sanofi and Regeneron Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA Read More>

April 24, 2017: Sanofi and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Read More>

April 5, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee Read More>

March 28, 2017: Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis Read More>


Genzyme India 15 year anniversary